Table 1.
Main characteristics of the study population.
| Belatacept (n=9) |
Tacrolimus (n=14) |
p value | |
|---|---|---|---|
| Time after transplantation (years) | 9.67 ± 4.19 | 3.5 ± 4.27 | 0.003 |
| Recipient age (years) | 60.8 ± 10.3 | 54.9 ± 12.3 | 0.25 |
| Recipient gender (Male) (n, %) | 8 (89%) | 9 (64%) | 0.34 |
| Donor age (years) | 60.2 ± 17.5 | 54.8 ± 13.4 | 0.51 |
| Transplant type | 0.82 | ||
| Living (n, %) | 1 (11%) | 1 (7%) | |
| DBD/DCD (n, %) | 6 (67%)/2 (22%) | 11 (79%)/2 (14%) | |
| Transplant number (1st) (n, %) | 7 (78%) | 10 (83%) | 0.48 |
| Time on dialysis (months) | 17.8 ± 18.3 | 34.3 ± 25 | 0.18 |
| Cause of ESRD (n, %) | 0.47 | ||
| Glomerular diseases | 4 (44%) | 5 (36%) | |
| Diabetic nephropathy | 0 | 1 (7%) | |
| Polycystic kidney disease | 1 (11%) | 3 (21%) | |
| Vascular/Hypertension | 1 (11%) | 2 (14%) | |
| Others | 3 (33%) | 1 (7%) | |
| Unknown | 0 | 2 (14%) | |
| Relevant comorbidities (n, %) | |||
| Diabetes | 0 | 2 (15%) | 0.49 |
| Hypertension | 6 (67%) | 11 (85%) | 0.61 |
| Heart failure | 1 (11%) | 2 (15%) | 1 |
| Previous splenectomy | 0 | 0 | |
| Induction treatment (n, %) | 0.39 | ||
| None | 1 (14%) | 0 | |
| Basiliximab | 7 (78%) | 11 (79%) | |
| rATG | 1 (14%) | 3 (21%) | |
| MMF dose (mg/d) | 826 ± 332 | 881 ± 227 | 0.66 |
| Prior anti-flu vaccination (n, %) | 7 (78%) | 12 (86%) | 1 |
| Type of vaccination (Vaxigrip) | 3 (33%) | 0 | 0.047 |
| cPRA at time of vaccination (%) | 10.2 ± 31 | 10.9 ± 22 | 0.95 |
| DSA at time of vaccination (n, %) | 0 | 2 (14%) | 0.17 |
| De novo DSA after vaccination (n, %) | 0 | 0 | 1 |
| Acute rejection prior to vaccination (n, %) | 1 (12.5%) | 2 (13%) | 1 |
| Acute rejection after vaccination (n, %) | 0 | 0 | 1 |
| eGFR at time of vaccination (mL/min/1.73m2) | 54.9 ± 22 | 63.9 ± 15 | 0.34 |